Patents by Inventor Carl-Johan Dalsgaard
Carl-Johan Dalsgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12213961Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.Type: GrantFiled: November 17, 2023Date of Patent: February 4, 2025Assignee: VICORE PHARMA ABInventors: Carl-Johan Dalsgaard, Rohit Batta
-
Patent number: 12128029Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.Type: GrantFiled: December 20, 2023Date of Patent: October 29, 2024Assignee: VICORE PHARMA ABInventors: Carl-Johan Dalsgaard, Rohit Batta
-
Publication number: 20240207232Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen.Type: ApplicationFiled: December 22, 2023Publication date: June 27, 2024Applicants: Vicore Pharma AB, Alex Therapeutics ABInventors: Johan RAUD, Carl-Johan DALSGAARD, Jessica SHULL, Kimmy BOLKE, Oliver FLEETWOOD
-
Publication number: 20240207231Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen.Type: ApplicationFiled: July 14, 2023Publication date: June 27, 2024Applicants: Vicore Pharma AB, Alex Therapeutics ABInventors: Johan RAUD, Carl-Johan Dalsgaard, Jessica Shull, Kimmy Bolke, Oliver Fleetwood
-
Publication number: 20240207230Abstract: Aspects of the present disclosure are directed to methods of treating an interstitial lung disease (ILD) in a patient, comprising administering a pharmaceutical treatment that is useful in the therapy of an ILD; and, in conjunction with the administration of the pharmaceutical treatment, engaging in a digital therapeutic program that delivers cognitive behavioural therapy for the treatment of anxiety which the patient identifies as leading to possible exacerbations of the symptoms of the ILD. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).Type: ApplicationFiled: February 24, 2023Publication date: June 27, 2024Applicants: Vicore Pharma AB, Alex Therapeutics ABInventors: Johan RAUD, Carl-Johan DALSGAARD, Jessica SHULL, Kimmy BOLKE, Oliver FLEETWOOD
-
Publication number: 20240122902Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.Type: ApplicationFiled: December 20, 2023Publication date: April 18, 2024Inventors: Carl-Johan DALSGAARD, Rohit BATTA
-
Publication number: 20240108604Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.Type: ApplicationFiled: November 17, 2023Publication date: April 4, 2024Inventors: Carl-Johan DALSGAARD, Rohit BATTA
-
Patent number: 11819494Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.Type: GrantFiled: February 25, 2022Date of Patent: November 21, 2023Assignee: VICORE PHARMA ABInventors: Carl-Johan Dalsgaard, Rohit Batta
-
Publication number: 20230248698Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.Type: ApplicationFiled: February 25, 2022Publication date: August 10, 2023Inventors: Carl-Johan DALSGAARD, Rohit BATTA
-
Publication number: 20220233480Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviates symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.Type: ApplicationFiled: January 20, 2022Publication date: July 28, 2022Inventors: Carl-Johan DALSGAARD, Johan RAUD, Rohit BATTA
-
Publication number: 20210401807Abstract: According to the invention, there is provided a pharmaceutical composition suitable for administration to the lung, which composition comprises a plurality of amorphous nanoporous silica particles, in which N-butyloxycarbonyl-3-(4-imidazol-1-yl-methylphenyl)-5-iso-butylthiophene-2-sulfonamide or a pharmaceutically-acceptable salt thereof is loaded into the pores of said silica particles, and wherein the silica particles have: (a) a mass median aerodynamic diameter that is between about 0.1 ?m and about 10 ?m; and (b) a geometric standard deviation that is less than about 4. Such compositions find particular utility in the treatment of an interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis, which diseases may be treated with such compositions for example by way of pulmonary administration.Type: ApplicationFiled: November 6, 2019Publication date: December 30, 2021Inventors: Carl-Johan DALSGAARD, Adam FEILER, Chunfang ZHOU, Paulina PASZKIEWICZ, Xin XIA
-
Publication number: 20210386712Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-thiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.Type: ApplicationFiled: August 27, 2021Publication date: December 16, 2021Inventors: Carl-Johan Dalsgaard, Johan Raud, Rohit Batta
-
Publication number: 20210290596Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.Type: ApplicationFiled: December 7, 2020Publication date: September 23, 2021Inventors: Carl-Johan Dalsgaard, Johan Raud, Rohit Batta
-
Patent number: 11123329Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.Type: GrantFiled: December 7, 2020Date of Patent: September 21, 2021Assignee: VICORE PHARMA ABInventors: Carl-Johan Dalsgaard, Johan Raud, Rohit Batta
-
Publication number: 20210236425Abstract: According to the invention, there is provided a pharmaceutical composition suitable for administration to the lung, which composition comprises a plurality of amorphous nanoporous silica particles, in which one or more immunomodulatory imide drug is loaded into the pores of said particles, and wherein the silica particles have: (a) a mass median aerodynamic diameter that is between about 0.1 ?m and about 10 ?m; and (b) a geometric standard deviation that is less than about 4, for use in the treatment of an interstitial lung disease by pulmonary administration. Preferred immunomodulatory imide drugs include thalidomide. Interstitial lung diseases that may be mentioned include idiopathic pulmonary fibrosis and sarcoidosis.Type: ApplicationFiled: May 3, 2019Publication date: August 5, 2021Inventors: Carl-Johan DALSGAARD, Adam FEILER, Chunfang ZHOU, Paulina PASZKIEWICZ, Xin XIA
-
Publication number: 20170112837Abstract: According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.Type: ApplicationFiled: April 22, 2016Publication date: April 27, 2017Inventors: Johan RAUD, Carl-Johan DALSGAARD, Goran TORNLING
-
Publication number: 20170112838Abstract: According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.Type: ApplicationFiled: August 12, 2016Publication date: April 27, 2017Inventors: Johan Raud, Carl-Johan Dalsgaard, Göran Tornling
-
Patent number: 9492454Abstract: According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.Type: GrantFiled: February 4, 2016Date of Patent: November 15, 2016Assignee: RSPR Pharma ABInventors: Johan Raud, Carl-Johan Dalsgaard, Jesper Säfholm
-
Publication number: 20160310493Abstract: According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.Type: ApplicationFiled: April 22, 2016Publication date: October 27, 2016Inventors: Johan RAUD, Carl-Johan DALSGAARD, Jesper SÄFHOLM
-
Publication number: 20160243122Abstract: According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.Type: ApplicationFiled: October 23, 2015Publication date: August 25, 2016Inventors: Johan RAUD, Carl-Johan DALSGAARD, Jesper SÄFHOLM